Other
Epicondylitis
5
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Epicondylitis is an early-stage landscape with 5 programs across 4 companies. The most active players are Alnylam Pharmaceuticals, Milestone Pharmaceuticals Inc., ZARS Pharma Inc.. 4 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
6
clinical trials
Completed4 · 67%
Active, not recruiting1 · 17%
Recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis
Recruiting·—·N/A·NCT06040203·240 enrolled
Arthroscopic Treatment Combined With PRP Injection for Refractory Elbow Epicondylitis
Active, not recruiting·—·N/A·NCT04556825·80 enrolled
Platelet Rich Plasma (PRP) in Chronic Epicondylitis
Completed·—·Phase 3·NCT01945528·86 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)